Triple Immunotherapy Combos Enter The Ovarian Cancer Fight

Numerous clinical studies of dual combinations of checkpoint inhibitors are underway, with or without conventional chemotherapy agents, but one of the first Phase Ib studies of a triple combination of immunotherapies in ovarian cancer that includes an investigational cancer vaccine is expected to report initial results in March 2017, and a Phase II trial of another similar triple combination should start in the next several months.

Both triple combinations involve Immunovaccine Inc.’s potential cancer vaccine DPX-Survivac to induce T-cell activation, low doses of cyclophosphamide that...